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respective patient subgroups were compared by log-rank testing as 
was done for other patient-related factors. Subsequently, a miR-walk 
database search was done to determine potential targets of the 
dysregulated miRNAs. 
Results: It was possible to segregate a distinct miRNA expression 
pattern (consisting of 29 miRNAs) in patients with GBM; this was 
different to a previously published one consisting of 30 miRNAs 
whereas both results are not directly comparable due to 
methodological differences. Both subgroups defined by the pattern 
had a significantly altered median overall survival from 226 to 544 
days (log-rank-test, p = 0.005). Pattern and prediction were 
independent of MGMT methylation status. Further prognostic factors 
could not be identified; even MGMT methylation status did not reach 
statistic significance in this dataset. 
Conclusions: This study introduces a new methodology that can be 
used for generating miRNA patterns which in turn could have 
prognostic impact in GBM patients. Array technology is a critical 
factor so that prospective trials with larger case numbers and a 
clearly defined work-flow/array design/background correction are 
needed to 1) generate further hypotheses, 2) make results between 
study groups comparable and 3) to validate these results.  
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Purpose/Objective: Although radiotherapy is generally effective in 
patients with painful bone metastases, up to 40% of patients do not 
obtain sufficient pain relief. Furthermore, 50% of patients eventually 
experience progressive pain. Hence, theoretically, a large patient 
group should be given reirradiation, especially since survival of cancer 
patients increases. Little is known about clinical patterns for 
reirradiation of painful bone metastases and its effectiveness in terms 
of pain palliation. In this historical cohort study we evaluated 
reirradiation of painful bone metastases and its effectiveness in 
clinical practice.  
Materials and Methods: Between January 2000 and July 2011, 282 
patients were reirradiated for painful bone metastases at our center. 
Reirradiation was defined as retreatment of a painful bone metastasis 
≥ 4 weeks after initial irradiation for pain. Response to treatment was 
defined as a decrease in pain at the reirradiated site, as reported by 
the patient at the physician’s interview in person or by telephone, 
between 2 to 12 weeks after retreatment. Median moment of 
response assessment was 4 weeks after reirradiation (range 2-12). 
Patient and treatment characteristics were retrospectively collected 
from patient records. McNemar’s test for dependent data was used to 
compare proportions. Overall pain response rate was calculated for 
patients with available follow-up.  
Results: At the time of writing, the data of 187 patients were 
available. Of those, 54% were male, mean age was 64.1±12.3 years. 
Primary tumors were prostate in 31% of patients, breast in 27%, lung 
in 14% and other primaries in 28% of patients. The reirradiated 
metastases were localized in the spine in 48% of patients, pelvis in 
34%, long bones in 5% and other locations in 13% of patients. At 
reirradiation, patients had a lower functional status, had more pain 
and used more pain medication compared to initial radiotherapy 
(table 1). Reasons for reirradiation were mostly progression after 
initial response in 77% of patients and less often insufficient response 
or no response (12% vs.11% of patients, respectively). Median time-to-
reirradiation was 7 months (range 1-164). Reirradiation schedules 
differed significantly for initial and reirradiation, with more non 
standard schedules used for reirradiation (table 1). Follow-up data on 
response were available in 128 of 187 patients (68%). The overall 
response rate was 66% (95% CI, 0.58-0.74). 
 
 
Conclusions: Response to reirradiation occurred in 66% of patients, 
although it must be noted that in clinical follow-up was relatively poor 
in this study. Updated results will be presented in April 2013. 
   
PD-0531   
Spinal instability, as defined by the spinal instability neoplastic 
score, is associated with radiotherapy failure 
J.M. van der Velden1, M. Huisman2, M. van Vulpen1, M.A.A.J. van den 
Bosch2, H.M. Verkooijen2, J.J. Verlaan3 
1University Medical Center Utrecht, Imaging Division Department of 
Radiation Oncology, Utrecht, The Netherlands  
2University Medical Center Utrecht, Imaging Division Department of 
Radiology, Utrecht, The Netherlands  
3University Medical Center Utrecht, Department Orthopaedic Surgery, 
Utrecht, The Netherlands  
 
Purpose/Objective: Recently, the Spinal Instability Neoplastic Score 
(SINS) was proposed to objectively determine spinal instability in 
patients with spinal metastases based on clinical and radiological 
examinations. The SINS score, ranging from 0 to 18 points, divides 
patients into three categories; stable (0-6), potentially unstable (7-12) 
and unstable (13-18). Early recognition of (impending) spinal 
instability may prevent painful collapse and neurologic deficits by 
timely referral for surgical stabilization. Presently, it is not known 
whether spinal instability negatively influences radiotherapy 
outcomes. The purpose of this study was to determine the effect of 
spinal instability, as defined by the SINS score, on radiotherapy 
failure.  
Materials and Methods: We performed a retrospective matched case-
control study in a radiotherapy-based patient population. Cases were 
defined as patients who underwent retreatment (reirradiation, 
surgical stabilization or conservative treatment) for symptomatic 
metastases of the thoracic or lumbar spine after radiation therapy. 
Controls did not undergo retreatment after radiation therapy and 
were matched for follow-up at a 2:1 ratio. Cases (N=41) and controls 
(N=82) were selected from all patients treated between January 2009 
and December 2010 at our center (N=712). Exclusion criteria applied 
were prior treatment or orthopedic consultation for the painful lesion, 
an aberrant radiotherapy regimen, intramedullar lesions and the use 
of multiple fields at initial radiotherapy. Age, sex, functional status 
(WHO< 1 or >2), primary tumor, localization, number of bone 
metastases, symptoms, radiotherapy schedule (1 x 8 or 5 x 4 Gy) and 
use of systemic therapy were retrieved from patients records. A spinal 
surgeon, blinded for the outcome, scored instability using the SINS 
criteria on the CT-scans of both cases and controls. Patient records 
were independently reviewed by two observers to determine the SINS 
component pain; discrepancies were reviewed by a radiation 
oncologist and consensus was obtained. Univariate and multivariate 
conditional logistic regression models were used for case-control 
comparison.  
Results: Retreatment consisted of reirradiation in 80%, surgery 10% 
and conservative management (intrathecal pump implant or plaster 
jacket) in 10%. The median SINS score was 9 (range 4-16) for cases and 
7 (range 1-16) for controls. After multivariate adjustment (Table 1), 
the total SINS score and the categorized SINS, were significantly and 
independently associated with radiotherapy failure (adjusted odds 
ratio for total SINS, 1.2; 95% CI, 1.1-1.5). 
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Conclusions: The results of this study suggest that increasing spinal 
instability, as defined by the SINS score, is associated with 
radiotherapy failure. Therefore, patients with (potentially) unstable 
painful spinal metastases should be considered for surgical 
stabilization first. 
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Purpose/Objective: Numerous treatment options are availables for 
recurrent high-grade gliomas (rHGG), including reirradiation. Both 
fractionated stereotactic radiotherapy (FSRT) and radiosurgery (SRS) 
represent an optimal method to deliver high-dose radiotherapy to the 
small volume. Reirradiation is often limited due to the dose-
prescription and target volume. The aim of this retrospective study 
was to evaluate the radiological and clinical efficacy of stereotactic 
radiotherapy for recurrent high-grade gliomas in terms of overall 
survival, radiological response and toxicity. 
Materials and Methods: Between 2004 and 2011, 128 patients (158 
lesions) with recurrent high-grade gliomas (63% Glioblastoma, WHO 
grade IV; 37% WHO grade III) were treated with CyberKnife 
stereotactic reirradiation. FSRT was performed in 96 lesions with 3-5 
fractions; SRS in 62 lesions. The median time from first irradiation and 
SRS reirradiation was 12 months (range 6-157 months). 
Results: Median survival time from the date of diagnosis was 32.1 
months (95% CI, range 25.2 to 42.9 months). Median survival time 
from the reirradiation treatment was 11,5 months (95% CI, range 10-
12 months). At 12 months, nineteen patients (15%) showed a 
radiological response (8% complete response) and at 6 and 12 months 
20 patients (16%) and 10 (8%) respectively showed a stable disease. 
There have been 19 patients (15%) of G1-G2 acute toxicity (with 
headhache, nausea, fatigue and alopecia) and 7 pts (6%) of G3-G4 late 
toxicity (radiation-induced necrosis and neurological deterioration). 
Conclusions: Salvage reirradiation with stereotactic radiotherapy for 
recurrent high-grade gliomas is safe and well tolerated. Radiographic 
response and duration of disease control suggest that this strategy is 
an effective treatment for recurrent HGG.  
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Purpose/Objective: Elderly patients with cancer represent a different 
population compared to younger patients. Comorbidity and declining 
performance may result in lesser outcome after palliative treatments. 
Our goal was to study the effect of age on response to radiotherapy 
and quality of life in patients with painful bone metastases. 
Materials and Methods: A large randomized radiotherapy trial showed 
equal effectiveness in pain relief of 8 Gy in a single fraction compared 
to 24 Gy in six fractions in patients with painful bone metastases. 
Between March 1996 and Sept 1998 1157 patients were included. At 
baseline and regular follow-up, patients completed questionnaires 
involving, among others, pain on an 11-point scale, several aspects of 
quality of life (QoL) (psychological distress, physical symptom distress, 
activity level impairment) and a verbally rated validation of QoL, all 
items derived from the Rotterdam Symptom Checklist. A visual analo-
gue score (VAS) of QoL was added. Response was calculated conform 
international standards. Patients were grouped into three age-
cohorts: A: 32-64 (n=520), B: 65-74 (n=410) and C: ≥ 75 years (n=227). 
For categorical variables, χ-square was used, for continuous variables, 
one-way ANOVA, with Bonferroni post-hoctesting. For survival and 
response analyses, the Kaplan Meier method and Cox-regression were 
used. 
Results: At baseline, visually and verbally rated QoL and QoL-
sumscores were available in 92%, 94% and 94% respectively. Elderly 
patients had worse performance at inclusion (Karnofsky Performance 
Score 20-60: 26%(A), 29%(B), 39%(C), p=0.004). When assessing base-
line QoL in different age groups, a difference in activity level was 
noticed (p<0.001, table 1), with significantly more impairment in 
group C compared to group B (p=0.01), and to A (p<0.001). Other QoL 
items were similar among age groups (table 1). During follow up, the 
decline in QoL was similar between the three age groups. Median 
survival was 35, 27 and 27 weeks for increasing age groups (p=0.05). 
Although elderly patients tended to respond less to radiation therapy 
compared to younger patients, there was still a significant response: C 
(67%) compared to A (78%, p=0.07), and to B (74%, p=0.36). No differ-
ences in mean time to response or between treatment arms were 
seen. In multivariate analysis, only primary tumor and performance 
score were significantly associated with response.  
 
 
Conclusions: Although at baseline elderly patients had a higher 
activity level impairment, and a worse performance score when 
compared to younger patients, they did not evaluate their overall QoL 
as inferior. Moreover, the majority of elderly patients showed a 
meaningful response to radiotherapy for painful bone metastases. 
Therefore, palliative radiotherapy should be considered in elderly 
patients.  
 
 SYMPOSIUM: RECURRENT GLIOMA/GBM  
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In recent years we have made remarkable progress in molecularly 
characterizing glioma uncovering their patho-genetic evolution and 
classifying them into different subtypes. Some of these molecular 
markers have been recognized to improve diagnostic precision and 
have a prognostic or even a predictive value for patient management 
based on retrospective analysis of clinical trials. Among these markers 
are mutations in the isocitrate dehydrogenase (IDH) 1 or 2 gene that 
